The promise of apolipoprotein A-I mimetics

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 2, 2010, Pages 171-176

  Mendez, Armando J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; High density lipoproteins; Peptides

Indexed keywords

5F PEPTIDE; APOLIPOPROTEIN A1; D 4F PEPTIDE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE; PEPTIDOMIMETIC AGENT; TANDEM HELICAL PEPTIDE; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY RISK; DISEASE COURSE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETIC MATERIALS; BIOMIMETICS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY;

EID: 77749323468     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283373cb5     Document Type: Review

References (57)

1. Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005; 118:1067-1077.
2. Toth PP. Novel therapies for increasing serum levels of HDL. Endocrinol Metab Clin North Am 2009; 38:151-170.
3. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a metaanalysis of 23 randomized lipid trials [miscellaneous article]. Curr Opin Lipidol 2006; 17:631-636.
4. Choi BG, Vilahur G, Yadegar D, et al. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006; 6:571-587.
5. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A1. Nature 1991; 353:265-267.
6. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994; 91:9607-9611.
7. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94:899-903.
8. Kalopissis AD, Chambaz J. Transgenic animals with altered high-density lipoprotein composition and functions [review]. Curr Opin Lipidol 2000; 11:149-153.
9. Escola-Gil JC, Calpe-Berdiel L, Palomer X, et al. Antiatherogenic role of highdensity lipoproteins: insights from genetically engineered-mice. Front Biosci 2006; 11:1328-1348; 1328-1348.
10. Writing Group. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106: 3143.
11. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113:2548-2555.
12. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96:1221-1232.
13. Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008; 7:365-375.
14. Sviridov D, Mukhamedova N, Remaley AT, et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008; 15:52-62.
15. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008; 9:196-203.
16. Rye KA, Bursill CA, Lambert G, et al. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50:S195-S200.
17. Ansell BJ. Targeting the anti-inflammatory effects of high-density lipoprotein. Am J Cardiol 2007; 100:n3-n9.
18. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15:158-161.
19. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30:151-155.
20. Olsson AG. Is high HDL cholesterol always good? Ann Med 2009; 41:11-18.
21. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 2006; 16:371-386.
22. Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50 (Suppl):S145-S149.
23. Friedman M, Byers SO, Rosenman RH. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp BiolMed 1957; 95:586-588.
24. Williams KJ, Werth VP, Wolff JA. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med 1984; 27:417-431.
25. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol 2008; 51:1098-1103.
26. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
27. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598.
28. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47:992-997.
29. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402.
30. Tardif JC, Gregoire J, L'Allier PL, et al., for the Effect of rHDL on Atherosclerosis- Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675-1682.
31. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre{beta}-HDL concentration in tissue fluid and stimulate reverse transport in humans. J Lipid Res 2001; 42:1586-1593.
32. Bisoendial RJ, Hovingh GK, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
33. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53:962-971.
34. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103:1084-1091.
35. Segrest JP, Jones MK, De Loof H, et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992; 33:141-166.
36. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331.
37. Anantharamaiah GM, Mishra VK, Garber DW, et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007; 48:1915-1923.
38. Datta G, Chaddha M, Hama S, et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001; 42:1096-1104.
39. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481-1494. (Pubitemid 30743598)
40. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41:1495-1508. (Pubitemid 30743599)
41. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290-292.
42. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42:545-552.
43. Getz GS, Wool GD, Reardon CA. Apoprotein A-I mimetic peptides and their potential antiatherogenic mechanisms of action. Curr Opin Lipidol 2009; 20:171-175.
44. Remaley AT, Amar M, Sviridov D. HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 2008; 6:1203-1215.
45. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre{beta} high-density lipoprotein and improves high-density lipoproteinmediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
46. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-1352.
47. Chung BH, Anatharamaiah GM, Brouillette CG, et al. Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. J Biol Chem 1985; 260:10256-10262.
48. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 1994; 94:1698-1705.
49. Yancey PG, Bielicki JK, Johnson WJ, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 2002; 34:7955-7965.
50. Wool GD, Reardon CA, Getz GS. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially antiatherogenic properties. J Lipid Res 2008; 49:1268-1283.
51. Sethi AA, Stonik JA, Thomas F, et al. Asymmetry in the lipid affinity of bihelical amphipathic peptides. J Biol Chem 2008; 283:32273-32282.
52. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010; 30:246-252.
53. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3:540-547.
54. Van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49:2302-2311.
55. Epand RF, Mishra VK, Palgunachari MN, et al. Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids. Biochim Biophys Acta 2009; 1788:1967-1975.
56. Tang C, Vaughan AM, Anantharamaiah GM, Oram JF. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res 2006; 47:107-114.
57. Chen X, Burton C, Song X, et al. An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration. Int J Biol Sci 2009; 5:489-499.